Form D
View Original Filing
Notice of Exempt Offering of Securities
Item 1. Issuer's Identity
Name of Issuer:
OREXIGEN THERAPEUTICS, INC.
Jurisdiction of Incorporation/Organization
DELAWARE
Year of Incorporation/Organization
Over Five Years Ago
Item 2 Issuer Principal Place of Business and Contact Information
3344 N. TORREY PINES CT.
SUITE 200
LA JOLLA, CA 92037
Phone Number:
subscription required
Item 3. Related Persons
Name
MICHAEL NARACHI
Address
subscription required
Relationship(s)
- EXECUTIVE OFFICER
- DIRECTOR
Clarification of Response
Item 3. Related Persons
Name
JOSEPH HAGAN
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
THOMAS CANNELL
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
PRESTON KLASSEN
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
LOUIS C BOCK
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
WENDY L DIXON
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
BRIAN H. DOVEY
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
DAVID J ENDICOTT
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
PETER K HONIG
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
PATRICK J MAHAFFY
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
LOTA S ZOTH
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
ECKARD WEBER
Address
subscription required
Relationship(s)
Clarification of Response
Item 4. Industry Group
PHARMACEUTICALS
Item 5. Issuer Size
Revenue Range (for issuer not specifying "hedge" or "other investment" fund in Item 4 above)
DECLINE TO DISCLOSE
Item 6. Federal Exemptions and Exclusions Claimed
Item 7. Type of Filing
New Notice
Date of First Sale in this Offering:
09/10/2015
Item 8. Duration of Offering
Does the issuer intend this offering to last more than one year?
Yes
Item 9. Type(s) of Securities Offered
- Equity
- Option, Warrant or Other Right to Acquire Another Security
- Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security
Item 10. Business Combination Transaction
Is this offering being made in connection with a business combination
transaction, such as a merger, acquisition or exchange offer?
No
Clarification of Response
Item 11. Minimum Investment
Minimum Investment accepted from any outside investor
0
Item 13. Offering and Sales Amounts
Total Offering Amount
90000000
Total Amount Sold
60000000
Total Remaining to be Sold
30000000
Clarification of Response
THE TOTAL OFFERING AMOUNT INCLUDES THE AGGREGATE MAXIMUM EXERCISE PRICE OF WARRANTS TO PURCHASE SHARES OF COMMON STOCK OF THE ISSUER. SUCH WARRANTS HAVE NOT YET BEEN EXERCISED.
Item 14. Investors
Securities in the offering have been or may be sold to persons
who do not qualify as accredited investors,
Number of non-accredited investors who already have invested in the offering:
Total number of investors who already have invested in the offering:
1
Item 15. Sales Commissions and Finders' Fees Expenses
Sales Commissions:
0.0
Finders' Fees
0.0
Clarification of Response
Item 16. Use of Proceeds
Provide the amount of the gross proceeds of the offering
that has been or is proposed to be used for payments to any of the persons required
to be named as executive officers,directors or promoters in response to Item 3 above.
0.0
Clarification of Response
Signature and Submission
Issuer Name
OREXIGEN THERAPEUTICS, INC.
Issuer Signature
/S/ JOSEPH HAGAN
Signer Name
JOSEPH HAGAN
Signer Title
EVP, CHIEF BUSINESS FINANCIAL OFFICER
Signature Date
09/14/2015